biocrates life sciences ag announces management change following acquisition
Innsbruck, Austria – Following its recent acquisition by Bruker Corporation,
biocrates life sciences ag, a leading provider of standardized metabolomics kits, software, and services, today announced a leadership transition. Moritz Seuster, who has served as Chief Executive Officer since 2020, will be stepping down.
The company’s Board of Directors, in coordination with Dr. Oliver Rinner as the new Managing Director of biocrates, has appointed CMO Dr. Sebastian Gottfried as Site Manager of biocrates. Under Moritz Seuster’s leadership, the company underwent a consistent digital transformation, which included the implementation of AI-powered cloud software and the digitalization of sales operations. Furthermore, the launch of a new metabolomics kit generation in 2025 marked the beginning of a new era in metabolomics, building a strong foundation that made it an attractive partner for acquisition.
“I’m incredibly proud of what we’ve built together at biocrates,” said Moritz Seuster. “With the support of Bruker, the company is now wellpositioned for continued growth, and I’m confident that the new leadership will bring the energy and experience needed to lead it forward.”
Sebastian Gottfried brings extensive expertise in mass spectrometry-based omics and has been instrumental in shaping the biocrates brand in recent years. In his new role, he will focus on harnessing synergies throughout the integration process and advancing biocrates’ expansion into the
multiomics market. The new leadership remains firmly committed to supporting and driving innovation across a diverse landscape of mass spectrometry technologies and vendor platforms.
About biocrates life sciences ag
biocrates life sciences ag is the world leader in quantitative, mass-spectrometry-based metabolomics. Founded in 2002 and headquartered in Innsbruck, Austria, the company delivers standardized kits, software and contract research services that enable laboratories to quantify up to 1,800 biomarkers with a single kit from less than one drop of blood. Researchers worldwide rely on flagship kits such as MxP® Quant 1000 to transform metabolomic data from diverse tissues and sample types into actionable biomarkers, accelerated drug development and more precise healthcare.
Learn more at biocrates.com and follow biocrates on LinkedIn.
